دورية أكاديمية
أعرض في EDS

An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.

التفاصيل البيبلوغرافية
العنوان: An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.
المؤلفون: Prinz LF; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany. Electronic address: lars.prinz1@uk-koeln.de., Riet T; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Neureuther DF; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Lennartz S; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Chrobok D; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Hübbe H; Heidelberg University, 69117 Heidelberg, Germany., Uhl G; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Riet N; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Hofmann P; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Hösel M; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany., Simon AG; Institute of Pathology, University Hospital Cologne, 50937 Cologne, Germany., Tetenborg L; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Segbers P; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Shimono J; Department of Hematology, Oncology and Tumorimmunology, Charité University Medical Center Berlin, Benjamin Franklin Campus, 12203 Berlin, Germany., Gödel P; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany., Balke-Want H; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Flümann R; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany; Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine and University Hospital of Cologne, Cologne, Germany; Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, 50931 Cologne, Germany; University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, Hufelandstr. 55, 45147 Essen, Germany., Knittel G; University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, Hufelandstr. 55, 45147 Essen, Germany., Reinhardt HC; University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, Hufelandstr. 55, 45147 Essen, Germany., Scheid C; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany., Büttner R; Institute of Pathology, University Hospital Cologne, 50937 Cologne, Germany., Chapuy B; Department of Hematology, Oncology and Tumorimmunology, Charité University Medical Center Berlin, Benjamin Franklin Campus, 12203 Berlin, Germany., Ullrich RT; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany., Hallek M; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany., Chmielewski MM; Department I of Internal Medicine, University Hospital Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), 50931 Cologne, Germany. Electronic address: markus.chmielewski@uk-koeln.de.
المصدر: Cell reports. Medicine [Cell Rep Med] 2024 Feb 20; Vol. 5 (2), pp. 101421. Date of Electronic Publication: 2024 Feb 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2020]-
مواضيع طبية MeSH: T-Lymphocytes* , Lymphoma, Large B-Cell, Diffuse*/therapy , Lymphoma, Large B-Cell, Diffuse*/etiology, Humans ; Animals ; Mice ; CTLA-4 Antigen ; Immunotherapy, Adoptive/methods ; B-Lymphocytes ; Antigens, CD19/genetics
مستخلص: Chimeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory (r/r) B cell lymphomas but provides lasting remissions in only ∼40% of patients and is associated with serious adverse events. We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r) diffuse large B cell lymphoma (DLBCL) patients treated with tisagenlecleucel. This finding leads to the development of the CAR/CCR (chimeric checkpoint receptor) design, which consists of a CD19-specific first-generation CAR co-expressed with a recombinant CTLA-4-linked receptor with a 4-1BB co-stimulatory domain. CAR/CCR T cells demonstrate superior efficacy in xenograft mouse models compared with CAR T cells, superior long-term activity, and superior selectivity in in vitro assays with non-malignant CD19 + cells. In addition, immunocompetent mice show an intact CD80 - CD19 + B cell population after CAR/CCR T cell treatment. The results reveal the CAR/CCR design as a promising strategy for further translational study.
Competing Interests: Declaration of interests The authors declare no competing interests.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
References: Sci Immunol. 2018 Jul 6;3(25):. (PMID: 29980618)
Blood. 2023 May 18;141(20):2430-2442. (PMID: 36989488)
Lancet. 2020 Sep 19;396(10254):839-852. (PMID: 32888407)
N Engl J Med. 2018 Apr 12;378(15):1396-1407. (PMID: 29641966)
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):e118-e123. (PMID: 31948859)
Blood. 2021 Jan 21;137(3):323-335. (PMID: 32967009)
N Engl J Med. 2023 Jul 13;389(2):148-157. (PMID: 37272527)
N Engl J Med. 2016 Nov 10;375(19):1845-1855. (PMID: 27717298)
Cell. 2020 Apr 2;181(1):46-62. (PMID: 32243795)
Cochrane Database Syst Rev. 2021 Sep 13;9:CD013365. (PMID: 34515338)
Cancer J. 2020 May/Jun;26(3):206-216. (PMID: 32496454)
Clin Immunol. 2016 Dec;173:124-132. (PMID: 27717695)
Nat Med. 2018 May;24(5):679-690. (PMID: 29713087)
N Engl J Med. 2021 Feb 18;384(7):673-674. (PMID: 33596362)
N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
J Immunol. 2006 Oct 1;177(7):4464-72. (PMID: 16982882)
Nat Med. 2015 Jun;21(6):581-90. (PMID: 25939063)
Cell. 2020 Oct 1;183(1):126-142.e17. (PMID: 32961131)
Clin Cancer Res. 2019 Dec 1;25(23):7004-7013. (PMID: 31481504)
Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. (PMID: 30809033)
Blood. 2020 Aug 20;136(8):925-935. (PMID: 32582924)
Blood Cancer J. 2021 Jun 4;11(6):108. (PMID: 34088894)
Blood Cancer Discov. 2023 Jan 6;4(1):78-97. (PMID: 36346827)
Nat Med. 2022 Oct;28(10):2145-2154. (PMID: 36138152)
Immunity. 2023 Oct 10;56(10):2388-2407.e9. (PMID: 37776850)
Blood. 2023 May 11;141(19):2307-2315. (PMID: 36821768)
Cancer Cell. 2020 Apr 13;37(4):551-568.e14. (PMID: 32289277)
Pharmaceuticals (Basel). 2022 Mar 09;15(3):. (PMID: 35337133)
Blood. 2021 Sep 23;138(12):1081-1085. (PMID: 34041526)
Ther Adv Hematol. 2019 Apr 22;10:2040620719841591. (PMID: 31040936)
Immunity. 2016 Feb 16;44(2):380-90. (PMID: 26885860)
PLoS One. 2015 May 11;10(5):e0126765. (PMID: 25962156)
Clin Lymphoma Myeloma Leuk. 2021 May;21(5):309-317.e3. (PMID: 33632668)
Cell Discov. 2021 Sep 14;7(1):84. (PMID: 34518515)
J Clin Invest. 2016 Aug 1;126(8):3130-44. (PMID: 27454297)
Annu Rev Immunol. 2018 Apr 26;36:411-433. (PMID: 29677473)
Immunity. 2002 Aug;17(2):201-10. (PMID: 12196291)
Methods Mol Biol. 2020;2155:83-97. (PMID: 32474869)
Front Immunol. 2022 Apr 01;13:858021. (PMID: 35432352)
J Clin Oncol. 2019 Feb 20;37(6):481-489. (PMID: 30620669)
Leuk Lymphoma. 2014 Sep;55(9):2120-4. (PMID: 24283754)
Blood. 2023 May 18;141(20):2460-2469. (PMID: 36800563)
Nat Med. 2021 May;27(5):842-850. (PMID: 33888899)
Cell Rep. 2017 Oct 3;21(1):17-26. (PMID: 28978471)
Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. (PMID: 31456438)
Cancer Immunol Res. 2022 Sep 1;10(9):1055-1068. (PMID: 35759797)
Blood. 2022 Feb 17;139(7):1026-1038. (PMID: 34496014)
J Exp Med. 2008 Sep 29;205(10):2251-68. (PMID: 18794340)
Breast Cancer Res. 2022 Jun 3;24(1):39. (PMID: 35659040)
Cancer Discov. 2020 May;10(5):702-723. (PMID: 32193224)
Front Immunol. 2021 Jun 04;12:684642. (PMID: 34177932)
Cancer Discov. 2018 Aug;8(8):958-971. (PMID: 29880584)
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22699-22709. (PMID: 31636208)
JCI Insight. 2023 Oct 23;8(20):. (PMID: 37725442)
Cancer J. 2020 May/Jun;26(3):269-277. (PMID: 32496460)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Lancet Oncol. 2021 Oct;22(10):1403-1415. (PMID: 34516954)
Blood Rev. 2019 Mar;34:45-55. (PMID: 30528964)
Science. 1996 Mar 22;271(5256):1734-6. (PMID: 8596936)
فهرسة مساهمة: Keywords: CAR T cells; CD19; CD80; CD86; DLBCL; FL; checkpoint ligand; chimeric checkpoint receptor; lymphoma; neurotoxicity
المشرفين على المادة: 0 (CTLA-4 Antigen)
0 (Antigens, CD19)
تواريخ الأحداث: Date Created: 20240210 Date Completed: 20240223 Latest Revision: 20240229
رمز التحديث: 20240229
مُعرف محوري في PubMed: PMC10897622
DOI: 10.1016/j.xcrm.2024.101421
PMID: 38340727
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-3791
DOI:10.1016/j.xcrm.2024.101421